ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO895

Plasma Fibroblast Growth Factor 21 Plasma Concentration in Patients After Kidney Transplantation

Session Information

Category: Transplantation

  • 1802 Transplantation: Clinical

Authors

  • Adamczak, Marcin, Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland, Katowice, Poland
  • Bartmanska, Magdalena, Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland, Katowice, Poland
  • Wiecek, Andrzej, Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland, Katowice, Poland
Background

Fibroblast growth factor 21 (FGF21) is a protein hormone involved in the regulation of energy expenditure. The results of clinical studies suggest that plasma FGF21 concentration increases with the progression of chronic kidney disease. The aim of the present study was to analyze the effect of successful kidney transplantation on plasma FGF21 concentration and to study the factors related to plasma FGF21 concentration in patients long-term after kidney transplantation.

Methods

Forty patients with chronic kidney disease (CKD) 5 or 5D before kidney transplantation [27 women and 13 men aged 47.0 (39.3 - 54.0)], 180 patients long-term after kidney transplantation [70 women and 110 men aged 52 (47,4 – 54)] and 50 healthy subjects [28 women and 22 men aged 50.0 (47.6 - 58.0)] were enrolled into this study. In CKD patients, plasma FGF21 concentrations were measured four times (immediately before and 14 and 30 days, and 6 months after kidney transplantation). In patients long-term after kidney transplantation and in healthy subjects, this measurement was made once.

Results

In patients before kidney transplantation plasma FGF21 concentration were significantly higher than in healthy subjects [1013.0 pg/ml (744.4-1635.7 pg/ml) vs 256.0 pg/ml (219.0 – 332.0 pg/ml); p <0.001]. At 14, 30 days and 6 months after kidney transplantation, a significant decrease of plasma FGF21 was observed [1013.0 pg / ml (744.4 - 1635.7 pg / ml); 322.5 pg/ml (199.0 - 546.8 pg/ml); 367.5 pg/ml (289.3 - 483.5 pg/ml); 363.5 pg/ml (293.5 - 508.2 pg/ml) (p <0.001), respectively]. In patients long-term after kidney transplantation, a negative correlation was found between plasma FGF 21 concentration and estimated glomerular filtration (eGFR) (R = -0.165, p <0.05) and a positive correlations between plasma FGF21 concentration and HOMA (R = 0.185, p <0.02), BMI (R = 0.148, p <0.05) and serum triglycerides concentration (R = 0.362, p <0.001).

Conclusion

1. In patients after kidney transplantation a decrease of plasma FGF 21 concentration was found. 2. Plasma FGF21 concentration in patients long-term after kidney transplantation is related to the degree of impairment renal function and metabolic status.

Funding

  • Government Support - Non-U.S.